#USA #San Francisco #Cionic #Neural Sleeve #TRANSFORM Study

Cionic Unveils Groundbreaking Study for Upper Motor Neuron Conditions

Introduction to Cionic
Cionic, a San Francisco-based company that has pioneered the world's first FDA-cleared non-invasive closed-loop neuromodulation platform, has recently announced an innovative research initiative, the TRANSFORM study. Designed to assess the quality of life among adults affected by upper motor neuron (UMN) conditions, this study intends to capture extensive, longitudinal health data that is often overlooked in traditional clinical settings.

The Importance of the Study
With around 30 million Americans coping with mobility impairments due to UMN conditions, the need for comprehensive data regarding their experiences and challenges is paramount. Current assessments typically take place in sterile clinical environments and only at singular points in time, failing to reflect the nuanced lives of these individuals. The TRANSFORM study aims to change that narrative by gathering real-world data over a twelve-month period.

Study Design and Goals
The study will enroll approximately 1,000 adults with a variety of UMN conditions, including multiple sclerosis, strokes, spinal cord injuries, and cerebral palsy. Participants will be followed through six surveys distributed via the Cionic mobile application at specified intervals: one month, three months, six months, nine months, and twelve months from onboarding. This method allows respondents to complete surveys at their convenience, reinforcing the study's emphasis on real-life experiences.

The primary measure of the study will be the EQ-5D-5L, an established instrument for evaluating health-related quality of life, encompassing mobility, self-care, usual activities, pain and discomfort, as well as anxiety and depression. Additionally, secondary measures will hone in on specific symptoms prevalent in UMN conditions, namely spasticity, urinary incontinence, and fatigue.

Key Insights from Preliminary Findings
Dr. Rebecca Webster, Cionic’s Vice President of Clinical Operations, highlights that the goal is to develop a comprehensive dataset of quality-of-life metrics that reflects the daily realities faced by this population. Early results from the initial phase of the study show promising improvements, with participants reporting an average 26% enhancement in EQ-5D outcomes post-intervention. This reflects significant benefits across all measurement dimensions, pointing to a positive trend toward improved mobility, daily activities, self-care, and pain reduction.

Cionic Neural Sleeve: Enhancing Mobility
At the heart of this effort lies the Cionic Neural Sleeve—an FDA-cleared Class II prescription device that utilizes personalized electrical stimulation to engage muscles in both the upper and lower legs, thereby improving walking functionality in neurological conditions. This advanced device distinguishes itself from traditional approaches by coordinating muscle stimulation throughout the gait cycle rather than targeting just one muscle, leading to better overall mobility outcomes.

Impact on the Mobility Landscape
Since its FDA clearance four years ago, Cionic has made significant strides in revolutionizing care for mobility impairments. Recent statistics reveal that users have collectively completed over 750 million steps, with approximately 3 million hours of actual usage reported, underscoring the Neural Sleeve's integration into daily living. Furthermore, independent testing has shown a 94% improvement rate in gait performance among trial participants, signifying a robust endorsement of its effectiveness.

Community and Collaborative Efforts
Cionic's commitment does not end with technology. The company collaborates with a myriad of clinical, research, and advocacy entities, including leading institutions like Stanford University and the National Multiple Sclerosis Society, enabling wider dissemination and application of findings from the TRANSFORM study, and fostering enhanced support and resources for affected individuals.

Conclusion
The TRANSFORM study is a pivotal step towards not only enhancing the quality of life for adults with upper motor neuron conditions but also expanding the understanding and treatment options available to this underserved population. As Cionic continues to innovate and iterate on its technologies and research methodologies, the prospects for improved patient care are brighter than ever.

For more information about Cionic and the TRANSFORM study, visit Cionic's website.